For decades, the United States has led the world in biomedical research. That leadership was built deliberately over more than 80 years of sustained federal investment, strong academic institutions, and a unique ability to translate discovery into real-world therapies and technologies.

For those of us working in spine care, this system has been foundational. It has enabled research that informs clinical decisions, supported the development of new technologies, and created pathways that bring innovation from concept to patient care. In many ways, it is the invisible infrastructure behind everything we do.

In 2025, that infrastructure was tested in ways we have not seen in generations.

A series of policy changes quickly cascaded into widespread disruption across the biomedical research ecosystem. Proposals to cap indirect cost recovery at 15% immediately raised concerns about the financial viability of academic research institutions. At the same time, thousands of grants were frozen or terminated, particularly in areas such as vaccines, global health, and behavioral research. The National Science Foundation (NSF) canceled more than 1500 grants, while Department of Defense research programs experienced pauses and delays.

Compounding these actions were budget proposals that called for dramatic reductions in federal research investment, including cuts of up to 40% for the National Institutes of Health (NIH) and more than 40% for the Centers for Disease Control and Prevention.

Even as some of these actions were ultimately blocked by the courts or reversed through congressional intervention, the damage was already underway. Laboratories slowed or shut down. Hiring freezes spread across institutions. Investigators, particularly those early in their careers, found themselves navigating an environment defined by uncertainty rather than opportunity.

By the end of the fiscal year, more than 5500 fewer NIH grants had been funded compared to prior years, representing an 8.6% decline. Across NIH and NSF, an estimated 3800 grants had been terminated. These terminations represent delayed discoveries, interrupted careers, and lost momentum in fields that depend on continuity.

The disruption was not isolated to a single agency or funding stream. Across the federal research ecosystem, instability in leadership, funding priorities, and staffing created ripple effects that extended far beyond individual grants.

At NIH, shifting funding policies and administrative uncertainty compressed long-term research planning into shorter and less predictable cycles. NSF scaled back support for basic science and STEM programs, raising broader concerns about the future pipeline of scientific discovery and innovation. At the CDC, workforce disruptions weakened core public health functions, including disease surveillance and preparedness efforts that depend on continuity and institutional expertise.

For those of us in spine care, the effects are both direct and indirect. Reduced NIH funding limits the availability of grants supporting clinical and translational spine research. Delays within the FDA, driven in part by staffing constraints, also have the potential to slow the review of new devices and technologies. Interruptions in Department of Defense and Department of Energy programs affect areas such as biomaterials, imaging, and rehabilitation science, all of which contribute to spine innovation.

The workforce reduction and budget cuts at AHRQ have a disproportionate effect on health services research and implementation science. Health services research, including comparative effectiveness research, outcomes measurement, disparities, and patient-centered research, is in jeopardy. Implementation science - how we can move discoveries to bedside - are critically needed to improve patient and population health. These funding cuts at AHRQ put this work in jeopardy.

In short, spine innovation does not operate independently of the broader research ecosystem. When that system is disrupted, the effects extend across the continuum of discovery, development, and patient care.

Congress ultimately stepped in to prevent the most severe outcomes. Funding for NIH was preserved and even modestly increased. Proposed structural changes, such as consolidating institutes or capping indirect costs, were blocked. Additional oversight measures were implemented to increase transparency and accountability in how agencies manage future changes.

These actions were critical. They stabilized the system at a moment when confidence was rapidly eroding. However, stabilization is not the same as resolution.

The events of 2025 exposed underlying vulnerabilities that cannot be ignored. Chief among them is the degree to which the biomedical research enterprise depends on stable and predictable federal support. When that support becomes uncertain, even temporarily, the effects move quickly through institutions, careers, and ultimately patient care.

Some of the most significant impacts of this disruption are not immediately apparent. Research depends on continuity, and when projects are paused or funding is withdrawn, the effects are difficult to reverse. Data may be lost, teams disbanded, and promising lines of inquiry abandoned.

There are also early signs of longer-term consequences. PhD enrollment is beginning to stall as prospective trainees question the stability of research careers. Institutions are reporting increased difficulty recruiting and retaining talent, alongside growing concern about a potential “brain drain” as researchers explore opportunities in countries with more stable funding environments.

If sustained, these trends could reshape the future of biomedical innovation.

In response, the research community is adapting. Institutions are placing greater emphasis on diversifying funding sources, looking beyond traditional federal grants to philanthropy, state programs, and industry partnerships. Major philanthropic organizations have expanded their commitments, while several states are investing in new biomedical research initiatives.

Industry collaboration is also playing an increasingly important role. Partnerships between academic investigators and medical technology companies are becoming more central to advancing research and bringing innovations to market. International collaborations continue to expand as well, creating new opportunities while also introducing additional complexity.

Together, these shifts reflect a growing recognition that the future of biomedical research may depend on a more diversified funding landscape.

Within the scientific community, responses to these changes have varied. Some have adopted a defensive posture, focusing on preserving existing programs and navigating an increasingly uncertain environment. Others view recent congressional actions as evidence that the system ultimately held, and that a return to stability is possible.

But another perspective is also emerging: the events of 2025 may represent more than a temporary disruption. For some, they have become a catalyst for reexamining how biomedical research is supported and sustained.

This perspective recognizes that the current model, while extraordinarily successful, may also need to evolve. It calls for stronger engagement with policymakers, greater collaboration across sectors, and renewed discussion about how research is funded, conducted, and translated into practice.

For the spine community, these changes carry important implications.

Innovation in spine care depends on a delicate balance of clinical insight, scientific discovery, and technological advancement, all of which are influenced by the broader research ecosystem. When that ecosystem is under strain, the pace and direction of innovation can shift as well.

At the same time, these challenges create opportunities for new approaches and stronger collaboration. There is growing opportunity to strengthen partnerships with industry and accelerate pathways for translating new technologies into clinical use. Alternative funding models may also play a larger role in supporting early-stage innovation. In parallel, organizations like NASS can take a more visible role in advocacy, helping ensure that musculoskeletal research remains a national priority.

Initiatives that bring together surgeons, researchers, investors, and industry partners, such as those emerging within the NASS innovation portfolio, are particularly well positioned in this environment. They reflect the kind of collaborative and forward-looking approach that will likely become increasingly important in the years ahead.

The US biomedical research enterprise remains one of the world’s leading drivers of scientific innovation. The events of 2025 did not change that. But they did serve as a reminder that even highly successful systems are vulnerable to disruption.

For those of us in spine care, the years ahead will require engagement, adaptability, and leadership. The question is not simply how the system recovers, but how it evolves.

The spine community has an important role to play in shaping that future.